Judge sets aside Boston patent verdict
This article was originally published in Clinica
A US federal judge last week ruled that a $324.4 million coronary stent patent decision in late 2000 against Boston Scientific and in favour of Johnson & Johnson should be overturned. The damages were set aside in March 2002. A new trial has been ordered by the judge, who also ruled that the stent of a co-defendant, Medtronic AVE, did not infringe J&J's patent (see Clinica No 939, p 10). J&J believes it will be able to reinstate the decision on appeal.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.